Arrêt de service programmé du vendredi 10 juin 16h jusqu’au lundi 13 juin 9h. Pour en savoir plus
Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Study of Iron Piperazine-Based Chelators as Potential Siderophore Mimetics

Abstract : Gram-negative bacteria's resistance such as Pseudomonas aeruginosa and the Burkholderia group to conventional antibiotics leads to therapeutic failure. Use of siderophores as Trojan horses to internalize antibacterial agents or toxic metals within bacteria is a promising strategy to overcome resistance phenomenon. To combat the Pseudomonas sp, we have synthesized and studied two piperazine-based siderophore mimetics carrying either catecholate moieties (1) or hydroxypyridinone groups (2) as iron chelators. These siderophore-like molecules were prepared in no more than four steps with good global yields. The physicochemical study has highlighted a strong iron affinity since their pFe values were higher than 20. 1 possesses even a pFe value superior than those of pyoverdine, the P. aeruginosa endogenous siderophore, suggesting its potential ability to compete with it. At physiological pH, 1 forms mainly a 2:3 complex with iron, whereas two species are observed for 2. Unfortunately, the corresponding Ga(III)-1 and 2 complexes showed no antibacterial activity against P. aeruginosa DSM 1117 strain. The evaluation of their siderophore-like activity showed that 1 and 2 could be internalized by the bacteria.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-u-picardie.archives-ouvertes.fr/hal-03592256
Contributeur : Louise Dessaivre Connectez-vous pour contacter le contributeur
Soumis le : mardi 1 mars 2022 - 10:44:35
Dernière modification le : mercredi 11 mai 2022 - 12:30:08

Lien texte intégral

Identifiants

Collections

Citation

Pauline Loupias, Isabelle Dechamps-Olivier, Laurent Dupont, Pierre Vanlemmens, Catherine Mullie, et al.. Study of Iron Piperazine-Based Chelators as Potential Siderophore Mimetics. Pharmaceuticals, MDPI, 2019, 12 (4), ⟨10.3390/ph12040160⟩. ⟨hal-03592256⟩

Partager

Métriques

Consultations de la notice

34